Definitive Healthcare Corp. (NASDAQ:DH) Given Consensus Rating of “Hold” by Brokerages

Shares of Definitive Healthcare Corp. (NASDAQ:DH) have earned a consensus rating of “Hold” from the eight analysts that are presently covering the company, MarketBeat Ratings reports. Three equities research analysts have rated the stock with a sell rating, three have issued a hold rating, one has assigned a buy rating and one has assigned a strong buy rating to the company. The average 12 month price objective among brokerages that have issued a report on the stock in the last year is $2.7667.

Several analysts recently commented on DH shares. Wall Street Zen upgraded shares of Definitive Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, March 14th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Definitive Healthcare in a research note on Wednesday. Barclays reduced their price objective on shares of Definitive Healthcare from $2.75 to $1.00 and set an “underweight” rating for the company in a research note on Monday, March 30th. Canaccord Genuity Group reduced their price objective on shares of Definitive Healthcare from $4.00 to $3.00 and set a “hold” rating for the company in a research note on Friday, February 27th. Finally, Stephens reduced their price objective on shares of Definitive Healthcare from $3.00 to $2.00 and set an “equal weight” rating for the company in a research note on Friday, February 27th.

Definitive Healthcare Stock Down 1.1%

Shares of NASDAQ DH opened at $0.90 on Friday. The company has a quick ratio of 1.75, a current ratio of 1.75 and a debt-to-equity ratio of 0.81. Definitive Healthcare has a 52 week low of $0.80 and a 52 week high of $4.70. The firm has a 50-day moving average price of $0.98 and a 200 day moving average price of $1.69. The stock has a market capitalization of $94.65 million, a price-to-earnings ratio of -0.55, a price-to-earnings-growth ratio of 12.06 and a beta of 1.33.

Definitive Healthcare (NASDAQ:DH) last announced its quarterly earnings data on Thursday, May 7th. The company reported $0.06 EPS for the quarter, beating the consensus estimate of $0.03 by $0.03. Definitive Healthcare had a negative net margin of 76.04% and a positive return on equity of 4.04%. The firm had revenue of $55.93 million during the quarter, compared to analysts’ expectations of $55.02 million. Definitive Healthcare has set its Q2 2026 guidance at 0.030-0.040 EPS and its FY 2026 guidance at 0.160-0.19 EPS. Equities research analysts anticipate that Definitive Healthcare will post 0.05 EPS for the current fiscal year.

Hedge Funds Weigh In On Definitive Healthcare

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Raymond James Financial Inc. acquired a new position in Definitive Healthcare during the second quarter worth about $32,000. State of Alaska Department of Revenue raised its position in Definitive Healthcare by 109.3% during the fourth quarter. State of Alaska Department of Revenue now owns 11,433 shares of the company’s stock worth $32,000 after acquiring an additional 5,970 shares during the last quarter. Schonfeld Strategic Advisors LLC acquired a new position in Definitive Healthcare during the fourth quarter worth about $35,000. Ariadne Wealth Management LP acquired a new position in Definitive Healthcare during the third quarter worth about $54,000. Finally, Bayesian Capital Management LP acquired a new position in Definitive Healthcare during the second quarter worth about $55,000. Institutional investors and hedge funds own 98.67% of the company’s stock.

About Definitive Healthcare

Definitive Healthcare (NASDAQ:DH) is a leading provider of intelligence and analytics on healthcare providers, organizations and the professionals who treat patients. Through its cloud-based platform, the company aggregates data from multiple sources—including claims, government registries, commercial filings and proprietary research—to deliver a unified view of the healthcare landscape. Its solutions enable life sciences companies, healthcare providers, payers and consulting firms to identify market opportunities, optimize sales and marketing efforts, improve operational efficiency and support better patient outcomes.

The company’s flagship offering is a subscription-based data platform that features detailed profiles on physicians, hospitals, health systems and post-acute care facilities.